• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Poster: CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: LEUKEMIA & RELATED MALIGNANCIES Source Type: research

CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Context: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF risk remain unknown. Objective: To describe TTNT and TTD for CLL/SLL patients who initiated a first-line (1L) or second-or-later-line (2L+) therapy with ibrutinib or other regimens, in all patients and for subsets of patients with high baseline risk of AF/AF-related events.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: Acute Lymphoblastic Leukemia Source Type: research

Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-H élène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi Tags: Original Study Source Type: research

Saliva-omics in Plasma Cell Disorders-proof of concept and potential as a non-invasive tool for monitoring disease burden and MRD status.
Salivaomics has exciting potential for the diagnosis and monitoring of malignancy, evidence of which has been reported in oral cancer, head and neck malignancies and ovarian cancer. It has been observed that approximately 40% of cancer, stroke and cardiovascular disease biomarkers are present in whole saliva. Salivaomics has become an area of great interest in disease diagnosis over the last number of years, following the footsteps of the other "omics ” based diagnostic tools. Saliva is a fast, inexpensive and non-invasive method of sample collection therefore it might be considered as the biofluid of choice for the diag...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Ciara Tierney, Despina Bazou, Giao Le, Paul Dowling, Peter O'Gorman Source Type: research

A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States
There is limited information on the comorbidities and complications in elderly AML patients. In a sample of 3,911 AML patients ( ≥ 65 years) identified from the SEER-Medicare database, AML patients had more comorbidities, higher rates of complications, and a higher risk of developing cardiovascular disease, type 2 diabetes mellitus, and stroke compared to matched non-cancer controls.
Source: Clinical Lymphoma, Myeloma and Leukemia - April 29, 2019 Category: Hematology Authors: Neil Dhopeshwarkar, Shahed Iqbal, Xuehong Wang, Maribel Salas Tags: Original Study Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke included UTI, hypernatremia and acute renal failure.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman Source Type: research

Investigating the Mechanisms of Methotrexate Neurotoxicity in Patients With Childhood Leukemia and Long-Term Survivors
Adverse neurological events are common (4-20%) during treatment for pediatric acute lymphoblastic leukaemia (ALL) and include seizures, stroke like syndrome and leukoencephalopathy. In addition, chronic neurotoxicity is emerging as a worrying late effect of treatment with long-term survivors experiencing decreased executive function, processing speed and memory function. Survivors are also at increased risk of experiencing learning difficulties, social withdrawal issues and inattention hyperactivity disorders.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Victoria Forster, Jane Carr-Wilkinson, Deborah Tweddle, Sirintra Nakjang, Sanaa Choufani, Rosanna Weksberg, Frederik van Delft Source Type: research

Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
This retrospective study of 351 patients, who have undergone allogeneic hematopoietic stem cell transplantation between 2002 and 2011 at the University of Nebraska Medical Center, demonstrated 12% incidence of central nervous system complications. The most common complications included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and infection (9%). The 5-year overall survival was significantly lower among patients with versus without central nervous system complications (14% vs. 44%, p=0.0004).
Source: Clinical Lymphoma, Myeloma and Leukemia - June 18, 2015 Category: Hematology Authors: Vijaya Raj Bhatt, Vamshi Balasetti, Jagar J. Abduall, Smith Giri, James O. Armitage, Fausto R. Loberiza, R. Gregory Bociek, Philip J. Bierman, Lori J. Maness, Julie M. Vose, Pierre Fayad, Mojtaba Akhtari Source Type: research